Fig. 4
Combination of TEDbody with anti-OX40 agonistic Ab augments antitumor activity. A The treatment scheme for evaluating the effect of combination of either the TEDbody or a control Ab with either the anti-OX40 agonistic 1166/1167 Ab (anti-OX40) or the anti-PD1 antagonistic Ab (pembrolizumab: anti-PD1 in the figure) in conjunction with adoptive transfer of ex vivo-expanded CMVp-CTLs in NSG mice carrying a preestablished MDA-MB-231 orthotopic tumor xenograft (100–120 mm3). The arrows indicate each time point for a treatment or assay. B and E Tumor growth, measured as the average tumor volume, in response to the indicated treatment, as described in (A). Error bars: ±SEM (n = 9 to 11 per group). Data were pooled from two independent experiments with at least with four mice per group. C, D, F and G Tumor weight (C and F) and the number of tumor-infiltrating CMVp-CTLs per gram of a tumor and percentages of granzyme B-expressing tumor-infiltrating CMVp-CTLs (D and G), determined on day 3 after the last administration of the indicated treatment, as described in (A). Each symbol represents a value for one tumor from an individual mouse; midlines indicate the mean values. In (D) and (G), error bars denote ±SEM. In (B) to (G), *P < 0.05, **P < 0.01, and ***P < 0.001 indicate a significant difference between the indicated groups or a significant difference from the inCT group (B and E), determined by one-way ANOVA with the Newman–Keuls post hoc test; ns: not significant